How it works:
Erlotinib blocks the EGFR tyrosine kinase enzyme, disrupting the signalling pathways that enable tumour growth and proliferation. It is especially effective in patients whose cancer exhibits EGFR mutations. Used as first-line therapy for NSCLC and in combination with chemotherapy for advanced pancreatic cancer.
Recommended for:
Patients with NSCLC and confirmed EGFR mutations
Individuals with locally advanced or metastatic pancreatic cancer
Cases resistant to previous chemotherapy
As part of personalised medicine based on tumour genetics
Non-small cell lung cancer with EGFR expression
Metastatic pancreatic cancer (with chemotherapy)
Recurrent or progressive EGFR-positive cancers
Take orally at least one hour before or two hours after food, without chewing. The typical daily dose is 150mg, adjustable based on tolerance and response. Regular monitoring of liver function, renal function, and dermatologic side effects is recommended.
Hypersensitivity to erlotinib or formulation ingredients
Pregnancy and lactation
Severe hepatic impairment
Concurrent use of strong CYP3A4 inhibitors/inducers without medical supervision
Skin reactions: rash, dryness, itching
Gastrointestinal: diarrhoea, nausea, loss of appetite
General: fatigue, headache
Liver enzyme elevation
Rare: interstitial lung disease
Possible allergic responses
